Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
Date:3/20/2009

bination with a standard dosage of docetaxel. Eligible patients included those who have been diagnosed with advanced or metastatic solid tumours that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists.

The poster presentation will be available on the Oncolytics website today at www.oncolyticsbiotech.com.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented at this meeting with respect to REOLYSIN(R), the Company's expectations related to the results of trials investigating delivery of REOLYSIN(R), the Company's analysis of the results of the REOLYSIN(R)/docetaxel trial and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize RE
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
2. Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
3. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America
4. Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent
5. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
6. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
7. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
8. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
9. Oncolytics Biotech Inc. Announces 2008 Third Quarter Results
10. Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
11. Oncolytics Biotech Inc. Announces Clinical Update Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
(Date:12/24/2014)... Dec. 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... on December 22, 2014, thereby completing the U.S. ... the acquisition of the Company by Merck KGaA, ... satisfies another condition to closing the transaction, which ...
(Date:12/24/2014)... and NEW YORK , Dec. 23, ... open-label pilot study of mazindol in children with attention ... Therapy in December 2014 . The ... children with attention deficit/hyperactivity disorder" ( Konofal et al, ... Dec 1;8:2321-2332. eCollection 2014 ) shows that mazindol ...
(Date:12/22/2014)... Dec. 22, 2014   Synthetic Biologics, ... of pathogen-specific therapies for serious infections and ... microbiome, today announced positive topline safety and ... trial of SYN-004, the Company,s investigational oral ... Clostridium difficile (C. difficile) infection, antibiotic-associated ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... Missouri Coalition for,Lifesaving Cures revealed today a ... filed last week by opponents of embryonic stem,cell ... unsound that it,would exclude Missourians with common chromosomal ... definition of "human." In their blind rush ...
... the largest,privately held spinal implant manufacturer in the world, ... 2007. The company recorded,revenues of $30.2 million for the ... million it achieved in the same quarter a year ... in series E financing to,fund Globus, continued rapid growth. ...
... The American Stock Exchange(R),(Amex(R)) today lists the common ... Neuralstem, Inc. is a biotechnology company focused ... in the field of,regenerative medicine. "We proudly ... McGonegal, Senior Vice President of Amex,s Equities Group. ...
Cached Biology Technology:New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human 2Globus Medical Announces Record 2nd Quarter 2007 Results 2
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here before: ... but can,t remember your password, site key or the answer ... your first grade teacher? Today, Hoyos ... app that will finally put an end to the ... 1U TM . 1U leverages a user,s smartphone to ...
(Date:12/10/2014)... California , December 9, 2014 ... with ITN,s BCARD Platform   ... cloud-based enterprise meeting scheduling solutions for business-to-business (B2B) ... the world leader in mobile near-field communication (NFC), ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , ...
(Date:12/3/2014)... 2014 As part of our commitment to ... pleased to announce the release of a new reader ... the workforce data that they need. The ... by existing readers. Many such devices have serious shortcomings ... technology. Older models force users to navigate numerous complicated ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2
... tests in five lemur species show that fruit-eaters may have ... The results support the idea that relying on ... edge to individuals with certain cognitive abilities -- such as ... in the journal Animal Cognition , researchers Alexandra Rosati ...
... , PROVIDENCE, R.I. [Brown University] Here are two ... popular models for ecology research, and they are very ... new study about a bellwether community of two barnacle ... on competition between these two species if they experimentally ...
... has discovered a highly sexed mouse-like marsupial in Queensland,s ... the high-altitude regions of the World Heritage Area.,It,s the ... Dr Andrew Baker,s research team has discovered in the ... said he suspected the rare, Black-tailed Antechinus was a ...
Cached Biology News:Fruit-loving lemurs score higher on spatial memory tests 2Fruit-loving lemurs score higher on spatial memory tests 3Temperature and ecology: Rival Chilean barnacles keep competition cool 2Temperature and ecology: Rival Chilean barnacles keep competition cool 3Newly discovered marsupial the victim of fatal attraction 2
Pronase Reagent...
Rabbit polyclonal to ECSIT ( Abpromise for all tested applications). entrezGeneID: 51295 SwissProtID: Q96HQ7...
Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide...
Raised to arginine vasopressin coupled to bovine thyroglobulin with carbodiimide ....
Biology Products: